Metabolic Syndrome and the Risk of Mild Cognitive Impairment and Progression to Dementia: Follow-up of the Singapore Longitudinal Ageing Study Cohort.

Published

Journal Article

The association of the metabolic syndrome (MetS) and component cardiovascular risk factors with the risk of developing mild cognitive impairment (MCI) and MCI progression to dementia is not well established.To investigate the association of the MetS and its component cardiovascular risk factors with the incidence of MCI and its progression to dementia.Prospective longitudinal study from September 1, 2003, through December 31, 2009, in communities in 5 districts in the South East region of Singapore. Study participants were a population-based sample of 1519 cognitively normal adults 55 years and older.Prespecified outcomes were incident MCI and MCI progression to dementia.The study cohort comprised 1519 participants. Their mean (SD) age was 64.9 (6.8) years, and 64.8% (n = 984) were female. Baseline characteristics associated with an increased risk of incident MCI were MetS (hazard ratio [HR], 1.46; 95% CI, 1.02-2.09), central obesity (HR, 1.41; 95% CI, 1.01-1.98), diabetes mellitus (HR, 2.84; 95% CI, 1.92-4.19), dyslipidemia (HR, 1.48; 95% CI, 1.01-2.15), and 3 or more component cardiovascular risk factors (HR, 1.58; 95% CI, 1.13-2.33). Baseline characteristics associated with an increased risk of MCI progression to dementia were MetS (HR, 4.25; 95% CI, 1.29-14.00), diabetes mellitus (HR, 2.47; 95% CI, 1.92-4.19), and 3 or more component cardiovascular risk factors (HR, 4.92; 95% CI, 1.39-17.4).The MetS was associated with an increased incidence of MCI and progression to dementia. Identifying individuals with diabetes mellitus or the MetS with or without MCI is a promising approach in early interventions to prevent or slow progression to dementia.

Full Text

Duke Authors

Cited Authors

  • Ng, TP; Feng, L; Nyunt, MSZ; Feng, L; Gao, Q; Lim, ML; Collinson, SL; Chong, MS; Lim, WS; Lee, TS; Yap, P; Yap, KB

Published Date

  • April 2016

Published In

Volume / Issue

  • 73 / 4

Start / End Page

  • 456 - 463

PubMed ID

  • 26926205

Pubmed Central ID

  • 26926205

Electronic International Standard Serial Number (EISSN)

  • 2168-6157

International Standard Serial Number (ISSN)

  • 2168-6149

Digital Object Identifier (DOI)

  • 10.1001/jamaneurol.2015.4899

Language

  • eng